TMEM106C

Across TCGA pan-cancer cohorts, TMEM106C RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated TMEM106C data layer compared with 3 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TMEM106C RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM106C expression acts as an unfavorable survival marker, although some lineages such as OV and STAD show a favorable association.

ACC, MESO, and LIHC are the cancer types where TMEM106C RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.239	0.688	<.001	112	view →
MESO	OS	Median	All	0.279	0.497	<.001	108	view →
LIHC	OS	Median	All	0.574	0.793	<.001	104	view →
LGG	OS	Median	All	0.704	0.924	<.001	54	view →
OV	DFS	Tertile	III,IV	0.562	0.452	.008	42	view →
STAD	DFS	Quartile	II,III,IV	0.624	0.338	.003	40	view →
ESCA	DFS	Median	III,IV	0.266	0.593	<.001	31	view →
COAD	OS	Quartile	IV	1.000	0.218	.003	27	view →
HNSC	OS	Median	All	0.244	0.511	.001	20	view →
READ	OS	Quartile	IV	0.297	0.889	.004	10	view →
LAML	DFS	Quartile	All	0.348	0.594	.027	10	view →
KIRC	OS	Tertile	All	0.693	0.556	.019	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

TMEM106C–ACC (DFS)

Open the ACC breakdown →